Request a quote, get detailed information on sample types, or learn how metabolomics can accelerate your research.
Biopharma companies generate more biological data than ever. The challenge is resolving which signals matter, which mechanisms are driving disease or treatment response, and where to invest next.
Metabolon uses comprehensive biochemical profiling to resolve complex biology. By measuring the biochemical products and processes closest to phenotype, metabolomics shows the functional result of what biology is actually doing.
Resolving biology is about moving beyond the detection of molecular signals to understand their biological consequences. It means connecting upstream multiomic data to active biochemical pathways, meaningful mechanisms, observable outcomes, and better-informed development decisions.
By bringing biological function into clearer resolution, Metabolon helps organizations turn molecular complexity into more actionable scientific evidence.
Multiomics research can generate thousands of signals across genes, RNA, proteins, metabolites, clinical measurements, and other molecular layers. Detecting a signal, however, is not the same as understanding what it means.
Resolving biology requires connecting these upstream molecular signals to their downstream functional consequences.
Through biochemical profiling, Metabolon helps organizations determine whether a molecular signal is associated with meaningful biological activity. This functional context can turn multiomic complexity into clearer biological understanding and more confident decisions.
Scientific uncertainty creates business risk. Therapeutic development requires substantial capital investment long before the biological potential of a target, biomarker, or development program is fully understood.
The earlier an organization can resolve meaningful biology from background noise, the better positioned it is to prioritize resources behind the strongest opportunities.
Metabolomics can provide an additional layer of biological evidence to help teams:
Better biological resolution leads to greater confidence in decision-making and more informed R&D investment.
Many biopharma organizations have already made significant investments in genomics, transcriptomics, proteomics, clinical data, artificial intelligence, and computational infrastructure. Metabolomics does not replace those investments. It gives them functional biological context.
By measuring downstream biochemical activity, biochemical profiling can help determine whether an upstream molecular signal produces a meaningful biological outcome. This is what resolving biology looks like in practice: moving from an observed association to a clearer understanding of its functional relevance.
Instead of simply identifying more signals, research teams can focus on determining which findings translate into meaningful biology, which hypotheses deserve further investigation, and which opportunities warrant continued investment.
Metabolon’s bioinformatics capabilities include:
Together, these capabilities create a more complete view of biology and help organizations generate greater value from existing research, technology, and data investments.
When metabolomics evidence influences R&D, clinical, or portfolio decisions, data quality matters. For more than 25 years, Metabolon has focused on generating accurate, reproducible, and biologically meaningful metabolomics data.
1,800,000+
Samples Analyzed
ISO 900:2015
Alignment across validated workflows
4,400+
Publications
CAP and CLIA
Certifications
5,400+
Level 1 and Level 2 annotated metabolites in a proprietary biochemical reference library
15,000+
Completed Projects
For executives and R&D leaders, metabolomics is not simply another analytical technology. Its value comes from helping answer high-consequence questions earlier:
By resolving biology earlier, leadership teams gain a stronger foundation for scientific prioritization, portfolio management, clinical strategy, and capital allocation.
In the largest metabolomic analysis to date in CAR T-cell therapy, Metabolon analyzed more than 3,800 patient samples across six clinical studies and identified metabolic signatures associated with severe neurological side effects.
Pathway-based risk scores developed from the analysis outperformed traditional inflammatory protein markers, demonstrating how metabolomics can reveal clinically relevant biology that may remain hidden when using other approaches.
By resolving metabolic patterns associated with neurological risk, the analysis provided a clearer view of functional biology and its potential clinical significance.
For biopharma leaders, the business implication is direct: deeper biological resolution can strengthen biomarker strategies, improve understanding of treatment response and safety, and reduce uncertainty around high-value development decisions.
See how Metabolon can help your organization resolve functional biology and support more confident R&D decisions.
In a multi-ethnic COPD study using the Metabolon Global Discovery Panel™, researchers identified 264 metabolites associated with lung function.
The researchers narrowed those findings to 49 metabolites with strong genetic instruments and ultimately identified eight metabolites with evidence of a causal relationship to COPD-related lung function.
The analysis connected biochemical changes to pathways involving:
By linking upstream genetic signals to downstream biochemical function, metabolomics helped resolve the biological path from association toward mechanism and potential therapeutic opportunity.
For R&D organizations, this type of multiomics analysis can support stronger target prioritization, greater confidence in biological hypotheses, and better-informed investment decisions.
Learn how Metabolon can help your organization resolve multiomic signals into functional biological insight and identify the opportunities most worth pursuing.
Speak with Metabolon Sales to learn how biochemical profiling can help your organization resolve biology and make more confident scientific and business decisions.
